Q32 Bio Inc (QTTB)

$5.90 +0.26 (4.61%)
Market Cap 82.51M
Revenue (ttm) 53.74M
Net Income (ttm) 29.82M
EPS (ttm) N/A
PE Ratio 4.66
Forward PE N/A
Profit Margin 55.49%
Debt to Equity Ratio 0.23
Volume 159,800
Avg Vol 258,692
Day's Range N/A - N/A
Shares Out 14.63M
Stochastic %K 13%
Beta -0.05
Analysts Strong Sell
Price Target $14.33

Company Profile

Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human anti–interleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical trials, designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 999 0232
Address:
830 Winter Street, Waltham, United States
anj_rew
anj_rew Apr. 1 at 1:54 PM
$QTTB Financially healthy, ADX-097 deal certainly helped, and bempikibart looks promising for Alopecia. Price target considers current financials, market cap, and future revenue potential with bempikibart. If bempikibart trials continue to show hair regrowth, including after the treatment period, in my opinion this price target is easily achievable. Not financial advice.
0 · Reply
scoon42
scoon42 Mar. 31 at 2:28 PM
$QTTB beat earnings last 4 quarters, this should be at least a $10 dollar stock , possibly a buyout candidate!
0 · Reply
HoHoHoHum
HoHoHoHum Mar. 30 at 8:39 AM
$QTTB looking to reenter
2 · Reply
Kwasy32
Kwasy32 Mar. 27 at 1:55 PM
$QTTB this stock is crazy .. moving calmly.. the explosion will be on massive on positive results
2 · Reply
scoon42
scoon42 Mar. 25 at 11:02 PM
$QTTB need to get the word out , needs a lot more volume
0 · Reply
Zwisch
Zwisch Mar. 24 at 7:54 PM
$QTTB Getting stronger!
0 · Reply
scoon42
scoon42 Mar. 23 at 11:30 PM
$QTTB one of these days going to pop and stay there , but needs more volume!
0 · Reply
ash1012
ash1012 Mar. 23 at 5:09 PM
$QTTB cna we see $8.00 this week
0 · Reply
topstockalerts
topstockalerts Mar. 20 at 1:31 PM
$QTTB thin names like this can go from dead to wild real quick. Pure momentum watch, needs volume or it just drifts.
0 · Reply
scoon42
scoon42 Mar. 20 at 1:29 PM
$QTTB Lift off🚀🚀🚀
0 · Reply
Latest News on QTTB
Q32 Bio to Participate in the 25th Annual Needham Virtual Healthcare Conference

Apr 8, 2026, 6:59 AM EDT - 5 hours ago

Q32 Bio to Participate in the 25th Annual Needham Virtual Healthcare Conference

Q32 Bio Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update

Mar 10, 2026, 6:59 AM EDT - 4 weeks ago

Q32 Bio Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update

Q32 Bio to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 18, 2026, 6:59 AM EST - 7 weeks ago

Q32 Bio to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Q32 Bio Announces $10.5 Million Registered Direct Offering

Feb 17, 2026, 6:59 AM EST - 7 weeks ago

Q32 Bio Announces $10.5 Million Registered Direct Offering

Dow Dips 200 Points; Q32 Bio Shares Jump

Dec 1, 2025, 9:58 AM EST - 4 months ago

Dow Dips 200 Points; Q32 Bio Shares Jump

Why Is Small-Cap Q32 Bio Stock Soaring On Monday?

Dec 1, 2025, 9:43 AM EST - 4 months ago

Why Is Small-Cap Q32 Bio Stock Soaring On Monday?

Q32 Bio Sells Complement Inhibitor ADX-097

Dec 1, 2025, 7:00 AM EST - 4 months ago

Q32 Bio Sells Complement Inhibitor ADX-097

AKBA

Q32 Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 13, 2025, 6:59 AM EST - 5 months ago

Q32 Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Q32 Bio Announces Completion of Enrollment in Part B of SIGNAL-AA Phase 2a Clinical Trial of Bempikibart for Alopecia Areata

Oct 21, 2025, 6:59 AM EDT - 6 months ago

Q32 Bio Announces Completion of Enrollment in Part B of SIGNAL-AA Phase 2a Clinical Trial of Bempikibart for Alopecia Areata

Q32 Bio to Participate in the 2025 Wells Fargo Healthcare Conference

Aug 28, 2025, 6:59 AM EDT - 7 months ago

Q32 Bio to Participate in the 2025 Wells Fargo Healthcare Conference

Q32 Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 6, 2025, 6:59 AM EDT - 8 months ago

Q32 Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Q32 Bio Appoints Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer

Jun 25, 2025, 6:59 AM EDT - 10 months ago

Q32 Bio Appoints Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer

Q32 Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 8, 2025, 6:59 AM EDT - 11 months ago

Q32 Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update

Q32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata

Apr 30, 2025, 6:59 AM EDT - 1 year ago

Q32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata

Q32 Bio Doses First Patients in Both Part A Open-Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia Areata

Apr 16, 2025, 6:59 AM EDT - 1 year ago

Q32 Bio Doses First Patients in Both Part A Open-Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia Areata

Q32 Bio Reports Fourth Quarter 2024 Financial Results and Provides Corporate Update

Mar 11, 2025, 6:59 AM EDT - 1 year ago

Q32 Bio Reports Fourth Quarter 2024 Financial Results and Provides Corporate Update

Q32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata at the 2025 American Academy of Dermatology Meeting

Mar 8, 2025, 11:00 AM EST - 1 year ago

Q32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata at the 2025 American Academy of Dermatology Meeting

Q32 Bio Announces Late-Breaking Presentation of Results from SIGNAL-AA Part A Clinical Trial of Bempikibart in Alopecia Areata at the 2025 American Academy of Dermatology Annual Meeting

Feb 28, 2025, 9:00 AM EST - 1 year ago

Q32 Bio Announces Late-Breaking Presentation of Results from SIGNAL-AA Part A Clinical Trial of Bempikibart in Alopecia Areata at the 2025 American Academy of Dermatology Annual Meeting

Q32 Bio to Participate in Upcoming March Investor Conferences

Feb 26, 2025, 6:59 AM EST - 1 year ago

Q32 Bio to Participate in Upcoming March Investor Conferences

Q32 Bio Announces Strategic Restructuring to Focus on Advancement of Bempikibart in Patients with Alopecia Areata

Feb 10, 2025, 4:05 PM EST - 1 year ago

Q32 Bio Announces Strategic Restructuring to Focus on Advancement of Bempikibart in Patients with Alopecia Areata

Q32 Bio to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Feb 4, 2025, 4:05 PM EST - 1 year ago

Q32 Bio to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Why Is Skin Disease-Focused Q32 Bio Stock Trading Lower On Wednesday?

Dec 11, 2024, 11:32 AM EST - 1 year ago

Why Is Skin Disease-Focused Q32 Bio Stock Trading Lower On Wednesday?

Q32 Bio Provides Bempikibart Program Update, Including Next Steps for Advancing Alopecia Areata Development Program

Dec 10, 2024, 4:05 PM EST - 1 year ago

Q32 Bio Provides Bempikibart Program Update, Including Next Steps for Advancing Alopecia Areata Development Program

Q32 Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 7, 2024, 6:59 AM EST - 1 year ago

Q32 Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Q32 Bio to Participate in Guggenheim's Inaugural Healthcare Innovation Conference

Nov 5, 2024, 6:59 AM EST - 1 year ago

Q32 Bio to Participate in Guggenheim's Inaugural Healthcare Innovation Conference

Q32 Bio to Present Tissue-Targeted Complement Inhibitor ADX-097 Positive Phase 1 Clinical Trial Results at the American Society of Nephrology Kidney Week 2024

Oct 14, 2024, 6:59 AM EDT - 1 year ago

Q32 Bio to Present Tissue-Targeted Complement Inhibitor ADX-097 Positive Phase 1 Clinical Trial Results at the American Society of Nephrology Kidney Week 2024

Q32 Bio to Participate in Upcoming September Investor Conferences

Aug 29, 2024, 6:59 AM EDT - 1 year ago

Q32 Bio to Participate in Upcoming September Investor Conferences

8 Best-Performing Small Caps In July: Find Out Which Stock Jumped 803%

Aug 1, 2024, 4:54 PM EDT - 1 year ago

8 Best-Performing Small Caps In July: Find Out Which Stock Jumped 803%

EBS HE HUMA SERV

Q32 Bio Announces Completion of Enrollment in the SIGNAL-AD Phase 2 Clinical Trial of Bempikibart for Atopic Dermatitis

Jul 9, 2024, 6:59 AM EDT - 1 year ago

Q32 Bio Announces Completion of Enrollment in the SIGNAL-AD Phase 2 Clinical Trial of Bempikibart for Atopic Dermatitis

Q32 Bio Joins Russell 3000® Index

Jul 1, 2024, 6:59 AM EDT - 1 year ago

Q32 Bio Joins Russell 3000® Index

Q32 Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 9, 2024, 6:59 AM EDT - 2 years ago

Q32 Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

Q32 Bio Appoints Lee Kalowski as President & Chief Financial Officer

Apr 3, 2024, 7:00 AM EDT - 2 years ago

Q32 Bio Appoints Lee Kalowski as President & Chief Financial Officer

Q32 Bio Announces Closing of Merger with Homology Medicines and Concurrent Private Placement of $42 Million

Mar 25, 2024, 4:15 PM EDT - 2 years ago

Q32 Bio Announces Closing of Merger with Homology Medicines and Concurrent Private Placement of $42 Million

anj_rew
anj_rew Apr. 1 at 1:54 PM
$QTTB Financially healthy, ADX-097 deal certainly helped, and bempikibart looks promising for Alopecia. Price target considers current financials, market cap, and future revenue potential with bempikibart. If bempikibart trials continue to show hair regrowth, including after the treatment period, in my opinion this price target is easily achievable. Not financial advice.
0 · Reply
scoon42
scoon42 Mar. 31 at 2:28 PM
$QTTB beat earnings last 4 quarters, this should be at least a $10 dollar stock , possibly a buyout candidate!
0 · Reply
HoHoHoHum
HoHoHoHum Mar. 30 at 8:39 AM
$QTTB looking to reenter
2 · Reply
Kwasy32
Kwasy32 Mar. 27 at 1:55 PM
$QTTB this stock is crazy .. moving calmly.. the explosion will be on massive on positive results
2 · Reply
scoon42
scoon42 Mar. 25 at 11:02 PM
$QTTB need to get the word out , needs a lot more volume
0 · Reply
Zwisch
Zwisch Mar. 24 at 7:54 PM
$QTTB Getting stronger!
0 · Reply
scoon42
scoon42 Mar. 23 at 11:30 PM
$QTTB one of these days going to pop and stay there , but needs more volume!
0 · Reply
ash1012
ash1012 Mar. 23 at 5:09 PM
$QTTB cna we see $8.00 this week
0 · Reply
topstockalerts
topstockalerts Mar. 20 at 1:31 PM
$QTTB thin names like this can go from dead to wild real quick. Pure momentum watch, needs volume or it just drifts.
0 · Reply
scoon42
scoon42 Mar. 20 at 1:29 PM
$QTTB Lift off🚀🚀🚀
0 · Reply
scoon42
scoon42 Mar. 20 at 12:39 PM
$QTTB Q32 Bio (QTTB) Upgraded to Strong Buy
0 · Reply
HeavyFt
HeavyFt Mar. 19 at 6:49 PM
$QTTB $10 order up
0 · Reply
scoon42
scoon42 Mar. 13 at 6:59 PM
$QTTB mark my words this will be $10 by May 1st
0 · Reply
STACKD0E
STACKD0E Mar. 13 at 2:16 PM
$QTTB +104% 🙃✨
0 · Reply
GoCoogs
GoCoogs Mar. 13 at 2:03 PM
$QTTB The march to $10 continues
0 · Reply
STACKD0E
STACKD0E Mar. 13 at 2:00 PM
$QTTB 🙃✨
0 · Reply
scoon42
scoon42 Mar. 13 at 12:32 PM
$QTTB 💰💰$8 today 💰💰
0 · Reply
HeavyFt
HeavyFt Mar. 12 at 6:08 PM
$CING and $QTTB Loaded more! ready for moon $TSLA $AAPL
0 · Reply
scoon42
scoon42 Mar. 12 at 4:38 PM
$QTTB up 94% the last month, plenty of momentum to continue, adding more shares load up!
0 · Reply
CEMBP_Trader
CEMBP_Trader Mar. 12 at 4:15 PM
$QTTB Bempikibart data mid year. ADX-096/Platform strategic news can do magic any time. 🍀🎉🍀 “Evaluating strategic next steps for ADX-096 and complement inhibitor platform”
0 · Reply